Efficacy and Safety of Tofacitinib in Anti–Melanoma Differentiation–Associated 5 Gene Antibody–Positive Dermatomyositis

From the ∗Department of Rheumatology, Key Laboratory of Myositis

†Outpatient Department

‡Department of Radiology, China-Japan Friendship Hospital, Beijing, China.

This research received National High Level Hospital Clinical Research Funding (2022-NHLHCRF-YS-02).

The authors declare no conflict of interest.

Correspondence: Lu Zhang, MD, No. 2 Yinghua East Street, Chaoyang District, Beijing, China. E-mail: [email protected]; Guochun Wang, MD, No. 2 Yinghua East Street, Chaoyang District, Beijing, China. E-mail: [email protected].

Supplemental digital content is available for this article. Direct URL citation appears in the printed text and is provided in the HTML and PDF versions of this article on the journal’s Web site (www.jclinrheum.com).

留言 (0)

沒有登入
gif